3.90.242.249
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Cardiology
Journal Scan

Study Provides Insights on Clinical Characteristics and Prognosis of Danon Disease

Posted on

Danon disease (DD), which is caused by mutations in the LAMP2 gene, is considered a multisystemic disease that is characterized by hypertrophic cardiomyopathy with pre-excitation and extreme hypertrophy, intellectual disability, myopathy, childhood presentation, and worse prognosis in men. However, these characterizations have been based on scarce data, which have since been disputed by a Spanish study that analyzed the clinical records of 27 patients (mean age, 31 years ± 19 years; 78% women) with DD treated at 10 Spanish hospitals.

The investigators found the following:

  • Male patients had a higher prevalence of extracardiac manifestations, including learning disorders (83%), myopathy (80%), and visual alterations (60%), all of which were rarely observed in women, affecting 5%, 0%, and 27% of women with DD, respectively;
  • Hypertrophic cardiomyopathy was the most common form of heart disease (61%), but the mean maximum wall thickness was 15 ± 7 mm;
  • Dilated cardiomyopathy was present in 12 patients, 10 of who were women;
  • Only 11 patients (49%) had pre-excitation;
  • 65% (n=16) of patients first presented with DD after age 20 years;
  • After a median follow-up of 4 years (interquartile range, 2-9), 4 men (67%) and 9 women (43%) died or required a transplant;
  • Cardiac disease and adverse events occurred later in women (37 ± 9 vs 23 ± 16 and 36 ± 20 vs 20 ± 11 years, respectively).

Read more here.

Reference

López-Sainz Á, Salazar-Mendiguchía J, García-Álvarez A, et al. Clinical findings and prognosis of Danon
disease. An analysis of the Spanish multicenter Danon registry. Rev Esp Cardiol (Engl Ed). 2018 Aug 11. pii: S1885-5857(18)30304-9. doi: 10.1016/j.rec.2018.04.035.

-Advertisement-
Related Articles
Evinacumab Cuts Cholesterol Levels by Half in Patients with HoFH
Jun 01, 2020
Considerations for Anesthesiologists Treating Patients with Cardiofaciocutaneous Syndrome
Mar 31, 2020
EHRA 2020 Cancels Meeting
Mar 18, 2020
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-